Pharmacology & ToxicologyEuropean Journal of Medicinal ChemistryPeer-reviewed
Targeting the Myeloid Immune Checkpoint ILT3 (LILRB4) with Small Molecules Enables Reprogramming of Suppressive Tumor Immunity
Somaya A. Abdel‐Rahman, Antonio Monari, Tom Miclot…·Moustafa Tarek Gabr
This study identifies small molecule modulators of ILT3, a myeloid immune checkpoint, showing anti-tumor efficacy in preclinical models.
DOI 10.1016/j.ejmech.2026.119295